-

GC Pharma Lights Up to Celebrate ‘World Hemophilia Day’

The Company features this year’s slogan image on media façade

YONGIN, South Korea--(BUSINESS WIRE)--GC Pharma (formerly known as Green Cross Corporation), a South Korean biopharmaceutical company, participates in a campaign to celebrate World Hemophilia Day.

As part of GC Pharma’s continued support of the hemophilia community, the company features this year's slogan image on a giant exterior media façade of its main campus in Yongin, South Korea.

Started in 1989 by the World Federation of Hemophilia (WFH), in honor of their founder Frank Schnabel’s birthday, World Hemophilia Day is celebrated each year on April 17th and intended to raise awareness of the disease and other bleeding disorders.

This year’s slogan is “Adapting to Change, sustaining care in a new world”. With this slogan, the global bleeding disorders community emphasizes the continuity of treatment for bleeding disorders, including haemophilia, in a world that has turned into Covid-19.

About Hemophilia

Hemophilia is a congenital disorder that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood. Hemophilia A is more common than hemophilia B; hemophilia A affects about 150,000 people, whereas hemophilia B affects about 30,000 people worldwide. Treatment regimens typically include on-demand and/or regular prophylactic infusions of factor replacement therapy to control or prevent the risk of bleeding. People with hemophilia, working closely with their healthcare professionals, can live healthy lives with proper care and adequate treatment.

About GC Pharma

GC Pharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions for more than half a century. Green Cross Corporation updated its corporate brand to GC Pharma in early 2018. Green Cross Corporation remains the company's registered, legal name.

Contacts

Media Contacts
HyunGoo Kang
gookang@gccorp.com

WooSub Shin
isswoo@gccorp.com

Yelin Jun
yelin@gccorp.com

Hansaem Kim
hs.kim@gccorp.com

GC Pharma

KRX:006280

Release Versions

Contacts

Media Contacts
HyunGoo Kang
gookang@gccorp.com

WooSub Shin
isswoo@gccorp.com

Yelin Jun
yelin@gccorp.com

Hansaem Kim
hs.kim@gccorp.com

More News From GC Pharma

GC Biopharma to Present New Data on Trends in Varicella Incidence Cases with Complications Among Korean Children at the 2022 ICPE

YONGIN, South Korea--(BUSINESS WIRE)--GC Biopharma (006280.KS) today announced that it will present new data demonstrating trends in the incidence of varicella cases with complications among Korean children during 2010-2020 after the universal one-dose varicella vaccination program. The date will be featured during a Spotlight Poster Discussion at the upcoming 2022 International Conference on Pharmacoepidemiology & Therapeutic Risk Management(ICPE 2022), taking place in Copenhagen, Denmark,...

GC Biopharma Reports Q2 2022 Results

YONGIN, South Korea--(BUSINESS WIRE)--GC Biopharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 30 June 2022. Second-Quarter Reported Results Key Figures Q2 2022 Growth(1) Total revenues KRW 423.2 billion 9.2% Operating Income KRW 13.1 billion 18.0% Net Income KRW 10.9 billion 45.3% (1) Results and percentages compare to Q2 2021 Financial Highlights Deliver...

GC Biopharma Reports Q1 2022 Results

YONGIN, South Korea--(BUSINESS WIRE)--GC Biopharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 31 March 2022. First-Quarter Reported Results Key Figures Q1 2022 Growth(1) Total revenues KRW 416.9 billion 47.7% Operating Income KRW 41.8 billion 736.0% Net Income KRW 18.0 billion 2.9% (1) Results and percentages compare to Q1 2021 Financial Highlights Delive...
Back to Newsroom